JSPR - Jasper Therapeutics to Present at Upcoming Investor Conferences in May | Benzinga
REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the following upcoming investor conferences in May:
Capital One Securities Biotech/Biopharma Disruptors Event
Conference Dates: May 14, 2024
Presentation Date: Tuesday, May 14 at 2:45 p.m. EDT
Presentation Format: Panel Discussion, "New Dermatology Treatments"
2024 RBC Capital Markets Global Healthcare Conference
Conference Dates: May 14 – 15, 2024
Presentation Date: Wednesday, May 15 at 3:35 p.m. EDT
Presentation Format: Fireside Chat
A live webcast of the RBC Conference fireside chat will be available on the Events & News – Presentations page of Jasper's Investor Relations website. An archived replay of the fireside chat will be available on Jasper's website for 30 days following the live broadcast.
About Jasper
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning ...